Dr. Mark D. Ewalt, M.D.
Pathology (Molecular Genetic Pathology (Pathology) Physician)
- Medicare participating
At a glance
- Medical school
- Columbia University College of Physicians and Surgeons (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 858
Licensed in California since 2012, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Columbia University College of Physicians and Surgeons
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Molecular Genetic Pathology (Pathology) Physician primary
CO license DR.0058760 (first issued 2017; expired) -
Cytopathology Physician
CO license DR.0058760 (first issued 2017; expired) -
Hematology (Pathology) Physician
CA license A121762 (first issued 2012; current) · CO license DR.0058760 (first issued 2017; expired)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
- Riverview Medical Center Red Bank, NJ
Medical groups
- Memorial PAthology Group (99 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 858
- Services billed
- 1,082
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Interpretation and report of genetic testing | 589 | 492 |
| Molecular pathology procedure; physician interpretation and report | 421 | 370 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 10 payments worth $27,228 in total to this clinician.
| Pillar Biosciences, Inc | $19,224 |
|---|---|
| Illumina, Inc. | $7,857 |
| Janssen Biotech, Inc. | $147 |
| Consulting Fee | $22,031 |
|---|---|
| Travel and Lodging | $4,915 |
| Food and Beverage | $283 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pillar Biosciences, Inc Dec 3, 2025 | Consulting Fee | $11,550 |
| Illumina, Inc. Sep 18, 2025 | Consulting Fee Oncology Testing · Genetics | $3,881 |
| Pillar Biosciences, Inc May 14, 2025 | Consulting Fee | $3,850 |
| Illumina, Inc. Aug 5, 2025 | Travel and Lodging Oncology Testing · Genetics · travel to Vienna, Austria · in-kind | $3,109 |
| Pillar Biosciences, Inc Oct 14, 2025 | Consulting Fee | $2,750 |
| Pillar Biosciences, Inc Dec 3, 2025 | Travel and Lodging travel to London, Great Britain (UK) | $938 |
| Illumina, Inc. Sep 18, 2025 | Travel and Lodging Oncology Testing · Genetics · travel to Vienna, Austria · in-kind | $488 |
| Illumina, Inc. Aug 5, 2025 | Travel and Lodging Oncology Testing · Genetics · travel to Vienna, Austria · in-kind | $380 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.